irinotecan has been researched along with Breast Cancer in 124 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 15 (12.10) | 18.2507 |
| 2000's | 42 (33.87) | 29.6817 |
| 2010's | 50 (40.32) | 24.3611 |
| 2020's | 17 (13.71) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, L; Feng, W; LaVoie, EJ; Liu, AA; Liu, LF; Satyanarayana, M; Tsai, YC | 1 |
| LaVoie, EJ; Liu, A; Liu, L; Pilch, DS; Rice, JE; Rzuczek, SG | 1 |
| Alsherbiny, MA; Bhuyan, DJ; Chang, D; Li, CG; Low, MN | 1 |
| Chung, YM; Hu, MC; Khan, PP; Larrick, JW; Qiao, Y; Tsai, WB; Wang, H; Yu, B | 1 |
| Harada, K; Hatanaka, K; Iwanaga, I; Kato, T; Kawamoto, Y; Komatsu, Y; Meguro, T; Nakamura, M; Nakano, S; Oba, K; Okuda, H; Sakamoto, N; Sakata, Y; Sato, A; Uebayashi, M; Yuki, S | 1 |
| Choi, CH; Lee, HJ | 1 |
| Johmura, Y; Miyoshi, Y; Nakanishi, M; Ohta, T; Taira Nihira, N; Togashi, Y; Wu, W; Zhu, D; Zhu, J | 1 |
| Bardia, A; Ciruelos, E; Cortes, J; Dalenc, F; Delaney, R; Fu, O; Jhaveri, KL; Lin, L; Loirat, D; Marmé, F; Pardo, PG; Rugo, HS; Schmid, P; Tolaney, SM; Trédan, O; Verret, W | 1 |
| Hamilton, E; Jacob, S; Rugo, HS; Shastry, M | 1 |
| Bai, Y; Gong, J; Huang, D; Ji, C; Li, J; Li, Y; Shen, L; Sun, Y; Wang, X; Wang, Z; Xin, Y; Xu, T; Zhang, X; Zhao, F | 1 |
| Daldrup-Link, HE | 1 |
| Abd El-Sadek, I; Lichtenegger, A; Makita, S; Matsusaka, S; Mori, T; Mukherjee, P; Shen, LT; Yasuno, Y | 1 |
| Ding, Z; Han, J; Hong, J; Liu, M; Liu, Y; Ma, Q; Zhang, H; Zhao, Y | 1 |
| Cai, Y; Chen, F; Chen, Y; Li, S; Luo, X; Wu, Z | 1 |
| Anan, K; Furusawa, H; Kai, Y; Kamada, Y; Mitsuyama, S; Miyara, K; Sagara, Y; Tamura, K; Tanaka, M; Tanaka, T; Uga, T | 1 |
| Anders, C; Belanger, B; Han, HS; Ma, C; Maxwell, F; Moore, Y; Munster, P; Northfelt, DW; Sachdev, JC; Thiagalingam, A; Wang, T; Zhang, B | 1 |
| Cai, S; Chen, L; Chen, Z; Lu, C; Tong, Y; Wang, M; Wang, Y; Wu, J; Yang, H | 1 |
| Chen, CC; Chen, CY; Cheng, SF; Chern, CY; Chi, YC; Chiu, YC; Kuo, YT; Lee, WC; Li, YC; Lin, PY; Liou, SJ; Tseng, ST; Tseng, WC; Wang, CA | 1 |
| Aldrich, J; Alemi, F; Anthony, SP; Arguello, D; Avramovic, S; Baldelli, E; Bellos, A; Carpten, JD; Conrad, A; Craig, DW; Dunetz, B; Gallagher, RI; Hodge, KA; Jahanzeb, M; Kemkes, A; Liotta, LA; Loesch, DM; Northfelt, DW; Petricoin, EF; Pierobon, M; Robert, NJ; Vocila, L; Wojtusiak, J; Wong, S; Wulfkuhle, JD | 1 |
| Keyvani-Ghamsari, S; Rabbani-Chadegani, A; Sargolzaei, J; Shahhoseini, M | 1 |
| Sahota, S; Vahdat, LT | 1 |
| Blaydorn, L; Coats, J; Farley, JH; Khemka, V; Lynch, CA; McGahey, K; Niu, J; Sangal, A; Waypa, J; Weiss, GJ | 1 |
| Abdel-Rahman, WM; Al-Khayyal, NA; Aravind, SR; Nair, VA; Saber-Ayad, M | 1 |
| Chen, Z; Li, S; Li, T; Liu, Y; Qin, X; Shen, X; Wu, C; Xie, X; Yang, H | 1 |
| Ahn, JH; Im, SA; Jung, KH; Kim, HJ; Kim, JH; Kim, SB; Kim, TY; Lee, KH; Lee, KS; Lee, S; Nam, BH; Park, IH; Park, KH; Park, YH; Ro, J; Sim, SH; Sohn, JH | 1 |
| Chen, J; Fan, Y; Hong, R; Ma, F; Ou, K; Sang, D; Wang, J; Xu, B; Yuan, P; Zhai, X; Zhao, C | 1 |
| Cheng, R; Li, X; Liu, Z; Lu, A; Sun, N; Tian, Z; Yang, Z; Zhao, C | 1 |
| Balslev, E; Brünner, N; Ejlertsen, B; Jakobsen, EH; Kümler, I; Nielsen, DL; Stenvang, J | 1 |
| Chalasani, P; Livingston, RB; Reed, D; Segar, JM; Stopeck, A | 1 |
| Balslev, E; Brünner, N; Kümler, I; Nielsen, DL; Stenvang, J | 1 |
| Boku, N; Fujiki, T; Fujino, K; Gemma, A; Kakihata, K; Masatani, S; Morita, S; Shiozawa, T; Tadokoro, J | 1 |
| Fujii, T; Iwakuma, N; Kakuma, T; Mishima, M; Otsuka, H; Shirouzu, K; Takahashi, R; Takenaka, M; Tanaka, M; Toh, U | 1 |
| Brünner, N; Nielsen, DL | 1 |
| Awada, A; Barrett-Lee, PJ; Chan, S; Chia, YL; Cocquyt, V; Coleman, RE; Garcia, AA; Hamm, JT; Hannah, AL; Hoch, U; Huizing, MT; Jerusalem, GH; Mehdi, A; O'Reilly, SM; Perez, EA; Sideras, K; Young, DE; Zhao, C | 1 |
| Cao, DY; Dun, JN; Fang, Y; Wang, J; Xiang, B; Xue, GQ; Zhang, L | 1 |
| Inaba, T; Ishida, K; Kashiwaba, M; Kawagishi, R; Komatsu, H; Matsui, Y; Sugai, T; Uesugi, N; Wakabayashi, G | 1 |
| Berek, JS; Chung, YM; Guan, M; Hu, MC; Hu, T; Ma, J; Ma, M | 1 |
| Mishra, MN; Palakurthi, S; Vangara, KK | 1 |
| Lan, H; Li, Y; Lin, CY | 1 |
| Hayakawa, Y; Lou, C; Saiki, I; Yokoyama, S | 1 |
| Balslev, E; Brünner, N; Kümler, I; Nielsen, D; Stenvang, J | 1 |
| Amzerin, M; Errihani, H; Mokrim, M; Piccart, MJ | 1 |
| Cuddington, BP; Ketela, T; Moffat, J; Mossman, KL; Workenhe, ST | 1 |
| Advani, PP; Crozier, JA; Hobday, T; Jaslowski, AJ; LaPlant, B; Moreno-Aspitia, A; Perez, EA | 1 |
| Adkins, CE; Eldon, MA; Hoch, U; Hye, T; Lockman, PR; Mohammad, AS; Mohan, NK; Nounou, MI; Terrell-Hall, T | 1 |
| Aluzaite, K; Brünner, N; Damsgaard, B; Do, KN; Foekens, J; Fogh, L; Gajjar, M; Hamerlik, P; Hansen, SN; Jandu, H; Knudsen, BR; Martens, J; Moreira, J; Nielsen, SL; Noer, JB; Pommier, Y; Proszek, J; Schrohl, AS; Smid, M; Stenvang, J; Stougaard, M; Thrane, SW | 1 |
| Bartlett, JM; Boutros, PC; Braunstein, M; Kalatskaya, I; Krzyzanowski, PM; Liao, L; Lobo, N; Lyttle, N; Marcellus, R; Spears, M; Stein, LD; Taylor, KJ; Twelves, CJ; Yao, CQ | 1 |
| Atherton, PJ; Grothey, A; Loprinzi, CL; Novotny, PJ; Sloan, JA; Thanarajasingam, G | 1 |
| Cardillo, TM; Chang, CH; Goldenberg, DM; Liu, D; Wang, Y; Zalath, M | 1 |
| Billadeau, DD; Cristofanilli, M; Cryns, VL; Gaisina, I; Giles, F; Jain, S; Kozikowski, A; Mazar, AP; O'Halloran, T; Ugolkov, A; White, K; Zhang, JS | 1 |
| Abe, N; Abe, S; Aoto, K; Kawana, S; Murakami, F; Ohtake, T; Okano, M; Suzuki, O; Tachibana, K; Takenoshita, S; Tasaki, K | 1 |
| Becerra, CR; Frenkel, EP; Tavana, D; Tran, HT; Verma, UN; Williams, NS | 1 |
| Choi, J; Gump, J; Lacevic, M; Lee, JH; Lush, R; Minton, S; Moulder, S; Munster, P; Neuger, A; Sullivan, D; Valkov, N | 1 |
| Algeciras-Schimnich, A; O'Kane, DJ; Snozek, CL | 1 |
| Fujii, S; Ikeda, M; Kurebayashi, J; Miyake, A; Nakashima, K; Nomura, T; Oota, Y; Seki, M; Shiiki, S; Shimo, T; Sonoo, H; Souda, M; Tanaka, K; Yamamoto, Y | 1 |
| Anderson, DM; Bernath, AM; Gamini, SS; Hillman, DW; Niedringhaus, R; Northfelt, DW; Palmieri, F; Perez, EA; Salim, M; Stella, PJ; Tan, WW | 1 |
| Choi, K; Rineer, J; Sanmugarajah, J | 1 |
| Ames, MM; Goetz, MP; Kuffel, MJ; Reinicke, KE | 1 |
| Fushimi, K; Kumagai, K; Nakano, S; Yamamoto, N | 1 |
| Arnaud, O; Bates, SE; Boumendjel, A; Di Pietro, A; Dumontet, C; Falson, P; Gèze, A; Guitton, J; Honorat, M; Matera, EL; Payen, L; Stein, WD | 1 |
| Aoki, M; Fujii, M; Murata, T; Oda, K | 1 |
| Hede, K | 1 |
| Azzariti, A; Cantore, M; Cassano, G; Colabufo, NA; Gasparre, G; Iannelli, G; Panaro, MA; Paradiso, A; Porcelli, L; Quatrale, AE; Tommasi, S | 1 |
| Hayashi, H; Masuda, N; Miyazaki, M; Morinaga, R; Nakagawa, K; Nakayama, T; Nishida, Y; Okamoto, I; Okamoto, W; Sakamoto, J; Satoh, T; Terashima, M; Tokunaga, Y; Tominaga, S; Tsurutani, J; Yamaguchi, M | 1 |
| Fukuda, K; Imai, Y; Ueda, Y; Yamagishi, H; Yoshimori, M | 1 |
| Aft, RL; Cai, S; Ellis, MJ; Goiffon, RJ; Guo, Z; Hoog, J; Li, S; Lin, L; Ma, CX; Piwnica-Worms, H; Prat, A; Ryan, CE; Schaiff, WT | 1 |
| Kanomata, N; Kozuka, Y; Kurebayashi, J; Moriya, T; Shimo, T; Sonoo, H; Yamashita, T | 1 |
| Lee, KS; Nam, BH; Park, IH; Ro, J | 1 |
| Choi, KC; Choi, KJ; Kim, SU; Yi, BR | 1 |
| Ambudkar, SV; Bhatnagar, J; Chen, JJ; Chen, WM; Chen, ZS; Lan, P; Ruan, ZX; Shu, C; Sodani, K; Wang, J; Xiao, ZJ; Ye, WC; Zhang, DM | 1 |
| Bernard, PS; Brenin, CM; Cai, SR; Craig Lockhart, A; Creekmore, AN; Dancey, J; Doyle, LA; Ebbert, M; Ellis, MJ; Fracasso, PM; Guo, Z; Ma, CX; Mwandoro, T; Naughton, MJ; Petroni, GR; Picus, J; Piwnica-Worms, H; Pluard, TJ; Reed, J; Ryan, CE; Watson, M; Yarde, ER | 1 |
| Huang, J; Mao, W; Shen, Y; Sui, M; Wang, J; Wu, X; Zhang, H | 1 |
| Shimada, T; Watanabe, A | 1 |
| Budman, DR | 1 |
| Agelaki, S; Alexopoulos, A; Ardavanis, A; Georgoulias, V; Kalbakis, K; Karyda, E; Kouroussis, Ch; Malamos, N; Malas, K; Tselepatiotis, E | 1 |
| Shapiro, CL; Xu, Y | 1 |
| Bowen, JM; Cummins, AG; Gibson, RJ; Inglis, MR; Keefe, DM | 1 |
| Botti, G; Capasso, I; Comella, G; Comella, P; D'Aiuto, G; De Rosa, V; Di Bonito, M; Frasci, G; Lapenta, L; Thomas, R; Vallone, P | 1 |
| Evans, SS; Harper, SM; Nagourney, RA; Radecki, S; Sommers, BL | 1 |
| Hirono, M; Ikeda, M; Kurebayashi, J; Nakashima, K; Nomura, N; Okubo, S; Sonoo, H; Tanaka, K; Udagawa, K; Yamamoto, Y | 1 |
| Doi, S; Ikegami, Y; Kitazaki, T; Kohno, S; Mizuta, Y; Murase, K; Nakamura, Y; Nakatomi, K; Oka, M; Ross, DD; Shiozawa, K; Soda, H; Tsurutani, J; Yoshida, H; Yoshikawa, M | 1 |
| Bates, SE; Blayney, M; Mistry, P; Morisaki, K; Polgar, O; Robey, RW; Steadman, K | 1 |
| Dakhil, SR; Fitch, TR; Hillman, DW; Ingle, JN; Kardinal, CG; Krook, JE; Kugler, JW; Mailliard, JA; Perez, EA; Rowland, KM; Ryan, JM | 1 |
| Paukstadt, W | 1 |
| Doi, S; Ikegami, Y; Itoh, A; Kitazaki, T; Kohno, S; Nakamura, Y; Nakatomi, K; Oka, M; Shiozawa, K; Soda, H; Tsurutani, J; Yoshida, H; Yoshikawa, M | 1 |
| Arima, T; Horino, K; Inoue, M; Kaneda, H; Kimura, M; Kuhara, H; Kume, S; Nakano, M; Nishimura, T; Uemura, K | 1 |
| Kosmas, Ch; Malamos, NA; Pergantas, N; Rigatos, SK; Stathopoulos, GP; Stathopoulos, JG; Tsavdaridis, D; Xynotroulas, J | 1 |
| André, T; Coudray, AM; De Gramont, A; Faivre, S; Gespach, C; Kornprobst, M; Larsen, AK; Louvet, C; Raymond, E; Tournigand, C | 1 |
| Botti, G; Comella, G; Comella, P; D'Aiuto, G; D'Aiuto, M; D'Aniello, R; De Rosa, V; Di Bonito, M; Frasci, G; Giordano, R; Lapenta, L; Thomas, R; Vallone, P | 1 |
| Amano, S; Enomoto, K; Negishi, N; Sakurai, K | 1 |
| Duncan, J; McLeod, HL; Scheffer, GL; Scheper, RJ; Shannon, WD; Zhang, W | 1 |
| Drummond, DC; Guo, Z; Hong, K; Kirpotin, DB; Noble, CO; Park, JW | 1 |
| Fujii, Y; Nakazawa, K; Shuzui, Y; Yoneto, T | 1 |
| Allen, WL; Galligan, L; Johnston, PG; Longley, DB; Rogers, KM; Sakai, H; Thomas, M; Wilson, TR | 1 |
| Komatsu, N; Makuuchi, H; Matsui, N; Mukai, M; Nakamura, M; Nakasaki, H; Ninomiya, H; Sato, S; Wakui, K | 1 |
| Boku, N; Yamazaki, K; Yoshino, T | 1 |
| Greenberger, LM; Horak, ID; Kraft, P; Longley, C; Malaby, J; Mehlig, M; Sapra, P; Zhao, H | 1 |
| Allen, J; Kolesar, J; Mrozek, E; Shapiro, CL; Villalona-Calero, M; Young, D | 1 |
| Hirose, S; Hojo, T; Ikeuchi, S; Isobe, Y; Kinoshita, T; Kubochi, K; Matsumoto, S; Sadako, AT; Shien, T; Terada, K | 1 |
| Taguchi, T | 1 |
| Doihara, H; Takashima, S; Yokoyama, N | 1 |
| Ishida, T; Morimoto, K; Ogawa, M; Ogawa, N; Taguchi, T; Tominaga, T | 1 |
| Ishida, T; Izuo, M; Nakao, I; Ogawa, M; Oguro, M; Ohkawa, T; Taguchi, T; Tominaga, T; Yoshida, M; Yoshida, Y | 1 |
| Sinha, BK; Wang, Z | 1 |
| Keith, WN; McLeod, HL | 1 |
| Armand, JP; Couteau, C; Terret, C | 1 |
| Jimbo, T; Kumazawa, E; Ochi, Y; Tohgo, A | 1 |
| Rosen, LS | 1 |
| Cottu, PH; Espie, M; Extra, JM; Lerebours, F; Marty, M | 1 |
| Mangold, G; Manikumar, G; Marty, J; Potter, PM; Vladu, B; Von Hoff, DD; Wadkins, RM; Wall, ME; Wani, MC; Weitman, S | 1 |
| Cameron, IL; Hardman, WE; Moyer, MP | 1 |
| Bates, SE; Brangi, M; Ciotti, M; Fojo, T; Kohlhagen, G; Litman, T; Nishiyama, K; Pommier, Y; Robey, R; Takimoto, C | 1 |
| Baldwin, AS; Cusack, JC; Liu, R | 1 |
| Ikeda, H; Koshiba, R | 1 |
| Kinoshita, H; Kou, M; Morimoto, K | 1 |
| Prescott, LM | 1 |
| Brunson, CY; Green, MR; Kneuper-Hall, R; Lal, A; Rocha Lima, CM; Urbanic, JJ | 1 |
| Bates, SE; Dean, M; Honjo, Y; Hrycyna, CA; Litman, T; Medina-Pérez, WY; Robey, RW; van de Laar, A; Yan, QW | 1 |
| Fujii, H; Igarashi, T; Imoto, S; Ishizawa, K; Itoh, K; Minami, H; Saeki, T; Sasaki, Y; Shigeoka, Y | 1 |
| Aiba, K; Akaza, H; Blackledge, G; Boku, N; Ikeda, T; Isonishi, S; Kato, M; Kawai, K; Mikami, O; Ohashi, Y; Saeki, T; Saijo, N; Sone, S; Stribling, D; Tsukagoshi, S; Tsuruo, T | 1 |
| Cummings, J; Jardine, L; Joel, SP; Okorokov, AL; te Poele, RH | 1 |
| Imai, Y; Ishikawa, E; Sugimoto, Y; Tsukahara, S; Tsuruo, T | 1 |
| Agrawal, S; Hang, J; Kandimalla, ER; Li, M; Shi, Z; Wang, H; Yu, D; Zhang, R | 1 |
| Furue, H; Hasegawa, K; Hattori, T; Niitani, H; Ohta, K; Taguchi, T; Wakui, A | 1 |
15 review(s) available for irinotecan and Breast Cancer
| Article | Year |
|---|---|
Sacituzumab govitecan: an antibody-drug conjugate.
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Camptothecin; Clinical Trials as Topic; Diarrhea; Female; Humans; Immunoconjugates; Irinotecan; Neoplasms; Neutropenia; Urologic Neoplasms | 2017 |
A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Camptothecin; Clinical Trials as Topic; DNA Topoisomerases, Type I; Female; Humans; Irinotecan; Neoplasm Metastasis; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 2013 |
[A Case of Primary Poorly Differentiated/Small Cell Carcinoma of the Breast in a Patient with Von Recklinghausen's Disease].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Irinotecan; Middle Aged; Neurofibromatosis 1 | 2016 |
Pharmacogenomics of tamoxifen and irinotecan therapies.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Colorectal Neoplasms; Cytochrome P-450 CYP2D6; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Pharmacogenetics; Polymorphism, Genetic; Tamoxifen; Treatment Outcome | 2008 |
Therapeutic potential of stem cells expressing suicide genes that selectively target human breast cancer cells: evidence that they exert tumoricidal effects via tumor tropism (review).
Topics: Breast Neoplasms; Camptothecin; Cytosine Deaminase; Female; Flucytosine; Fluorouracil; Ganciclovir; Genes, Transgenic, Suicide; Genetic Engineering; Genetic Therapy; Humans; Irinotecan; Prodrugs; Stem Cells; Thymidine Kinase | 2012 |
The search for enhanced therapeutic index in breast cancer: targeting the tumor and modulation of enzyme expression.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Breast Neoplasms; Camptothecin; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Design; Drug Synergism; Enzyme Induction; Epirubicin; Female; Fluorouracil; Humans; Irinotecan; Multicenter Studies as Topic; Neoplasm Proteins; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Thymidine Phosphorylase; Topoisomerase I Inhibitors; Treatment Outcome | 2002 |
Rationale for mitomycin and irinotecan use in advanced breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Maximum Tolerated Dose; Mitomycin; Women's Health | 2003 |
[Two cases of postoperative local skin recurrence of breast cancer successfully treated with chemotherapy of irinotecan hydrochloride (CPT-11)].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Carcinoembryonic Antigen; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Middle Aged; Mucin-1; Neoplasm Recurrence, Local; Skin Neoplasms | 2005 |
[Bevacizumab (Avastin)].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Colonic Neoplasms; Drug Administration Schedule; Drug Approval; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Lung Neoplasms; Male; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Vascular Endothelial Growth Factor A | 2007 |
[Recent advance in chemotherapy for breast cancer].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Docetaxel; Female; Humans; Irinotecan; Mitoxantrone; Paclitaxel; Randomized Controlled Trials as Topic; Salvage Therapy; Taxoids | 1994 |
CPT-11: the European clinical development.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Europe; Female; Humans; Irinotecan; Lung Neoplasms; Pancreatic Neoplasms; Uterine Cervical Neoplasms | 1996 |
Irinotecan in lymphoma, leukemia, and breast, pancreatic, ovarian, and small-cell lung cancers.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Irinotecan; Leukemia; Lung Neoplasms; Lymphoma; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms | 1998 |
[Clinical activity spectrum of irinotecan].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bronchial Neoplasms; Camptothecin; Carcinoma, Small Cell; Child; Clinical Trials as Topic; Digestive System Neoplasms; Disease-Free Survival; Drug Administration Schedule; Enzyme Inhibitors; Female; Genital Neoplasms, Female; Hematologic Neoplasms; Humans; Irinotecan; Male; Neoplasm Proteins; Neoplasms; Remission Induction; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome | 1998 |
[Irinotecan hydrochloride for treatment of advanced breast cancers].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Clinical Trials, Phase II as Topic; Female; Humans; Irinotecan; Topoisomerase I Inhibitors | 2000 |
Beyond pancreatic cancer: irinotecan and gemcitabine in solid tumors and hematologic malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Gemcitabine; Hematologic Neoplasms; Humans; Irinotecan; Lung Neoplasms; Lymphoma, Non-Hodgkin; Pancreatic Neoplasms | 2001 |
32 trial(s) available for irinotecan and Breast Cancer
| Article | Year |
|---|---|
Phase II Study of Continued Trastuzumab Plus Irinotecan in Patients with HER2-positive Gastric Cancer Previously Treated with Trastuzumab (HGCSG 1201).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Irinotecan; Receptor, ErbB-2; Stomach Neoplasms; Survival Rate; Trastuzumab | 2022 |
Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Capecitabine; Cyclin-Dependent Kinase 4; Female; Humans; Immunoconjugates; Irinotecan; Middle Aged; Receptor, ErbB-2; Vinorelbine | 2022 |
Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Immunoconjugates; Irinotecan; Topoisomerase Inhibitors; Triple Negative Breast Neoplasms | 2022 |
Trastuzumab Combined with Irinotecan in Patients with HER2-Positive Metastatic Colorectal Cancer: A Phase II Single-Arm Study and Exploratory Biomarker Analysis.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Female; Humans; Irinotecan; Phosphatidylinositol 3-Kinases; Rectal Neoplasms; Trastuzumab | 2023 |
Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Irinotecan; Survival Rate; Treatment Outcome; Triple Negative Breast Neoplasms | 2021 |
Multi-omic molecular profiling guide's efficacious treatment selection in refractory metastatic breast cancer: a prospective phase II clinical trial.
Topics: Breast Neoplasms; Female; Humans; Immunohistochemistry; Irinotecan; Prospective Studies; Treatment Outcome | 2022 |
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Docetaxel; Doxorubicin; Drug Eruptions; Fatigue; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasms; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Sarcoma; Small Cell Lung Carcinoma; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting | 2017 |
Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01).
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Drug Administration Schedule; Female; Humans; Irinotecan; Middle Aged; Progression-Free Survival; Quality of Life; Taxoids; Treatment Outcome | 2019 |
Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene.
Topics: Aged; Antineoplastic Agents; Biomarkers, Pharmacological; Breast Neoplasms; DNA Topoisomerases, Type I; Drug Therapy, Combination; Female; Gene Dosage; Humans; Irinotecan; Middle Aged; Predictive Value of Tests; Prognosis; Receptor, ErbB-2; Topoisomerase I Inhibitors; Trastuzumab; Treatment Outcome | 2019 |
A Phase II Study of Irinotecan and Etoposide as Treatment for Refractory Metastatic Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Etoposide; Female; Humans; Irinotecan; Middle Aged; Neoplasm Metastasis; Topoisomerase I Inhibitors | 2019 |
Phase II clinical trial of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium in metastatic and recurrent breast cancer.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Drug Combinations; Female; Glucuronosyltransferase; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Oxonic Acid; Polymorphism, Genetic; Pyridines; Survival Analysis; Tegafur; Treatment Outcome | 2015 |
Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Camptothecin; Drug Administration Schedule; Europe; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Intention to Treat Analysis; Irinotecan; Kaplan-Meier Estimate; Middle Aged; Polyethylene Glycols; Time Factors; Topoisomerase I Inhibitors; Treatment Outcome; United States | 2013 |
A phase I study of capecitabine combined with CPT-11 in metastatic breast cancer pretreated with anthracyclines and taxanes.
Topics: Adult; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Middle Aged; Taxoids | 2014 |
A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: a study protocol.
Topics: Breast Neoplasms; Camptothecin; DNA Topoisomerases, Type I; Drug Administration Schedule; Female; Gene Dosage; Genetic Markers; Humans; Irinotecan; Neoplasm Metastasis; Prospective Studies; Receptor, ErbB-2; Topoisomerase I Inhibitors; Treatment Outcome | 2015 |
N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing Therapy.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Cetuximab; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Salvage Therapy; Taxoids | 2016 |
Downregulation of histone H2A and H2B pathways is associated with anthracycline sensitivity in breast cancer.
Topics: Adult; Anthracyclines; Apoptosis; Breast Neoplasms; Camptothecin; Doxorubicin; Drug Resistance, Neoplasm; Epirubicin; Female; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histones; Humans; Irinotecan; MCF-7 Cells; Middle Aged; Signal Transduction; Young Adult | 2016 |
Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Camptothecin; Capecitabine; Deoxycytidine; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Epirubicin; Female; Fluorouracil; Gastrointestinal Diseases; Gastrointestinal Neoplasms; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Topoisomerase II Inhibitors; Treatment Outcome | 2008 |
Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Camptothecin; Chromatography, High Pressure Liquid; Deoxycytidine; DNA Topoisomerases, Type I; Female; Fluorescent Antibody Technique; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged | 2008 |
N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Irinotecan; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Camptothecin; Drug Resistance, Neoplasm; Feasibility Studies; Female; Humans; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Salvage Therapy; Topoisomerase Inhibitors; Young Adult | 2013 |
Phase II study of irinotecan plus capecitabine in anthracycline- and taxane- pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Middle Aged; Taxoids; Treatment Outcome | 2013 |
A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Female; Genes, p53; Humans; Irinotecan; Leukocytes, Mononuclear; Middle Aged; Mutation; Ribosomal Protein S6; Staurosporine; Treatment Outcome | 2013 |
Gemcitabine plus irinotecan in breast cancer patients pretreated with taxanes and anthracyclines: a multicenter phase II study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Irinotecan; Middle Aged; Treatment Outcome | 2003 |
Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Recombinant Proteins; Taxoids | 2004 |
Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both.
Topics: Adult; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Neoplasm Metastasis; Neoplasm Staging; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: a phase II study.
Topics: Adult; Aged; Anemia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Camptothecin; Disease Progression; Disease-Free Survival; Docetaxel; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neutropenia; Taxoids | 2005 |
Biweekly docetaxel-irinotecan treatment with filgrastim support is highly active in antracycline-Paclitaxel-refractory breast cancer patients.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Feasibility Studies; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Recombinant Proteins; Salvage Therapy; Taxoids | 2005 |
Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Female; Gene Expression; Humans; Irinotecan; Leukocytes, Mononuclear; Middle Aged; Mitomycin; NAD(P)H Dehydrogenase (Quinone); Neoplasm Metastasis; Polymorphism, Single Nucleotide | 2008 |
[A late phase II study of CPT-11 (irinotecan) in advanced breast cancer. CPT-11 Study Group on Breast Cancer].
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Diarrhea; Female; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Middle Aged | 1994 |
[An early phase II study of CPT-11 (irinotecan hydrochloride) in patients with advanced breast cancer].
Topics: Adult; Aged; Anorexia; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Middle Aged; Nausea; Neutropenia | 1994 |
[A pilot study of irinotecan hydrochloride for metastatic breast cancer--efficacy as a salvage therapy].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Camptothecin; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Irinotecan; Lymphatic Metastasis; Middle Aged; Pilot Projects; Salvage Therapy | 2000 |
[Phase I clinical study of CPT-11. Research group of CPT-11].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Drug Evaluation; Female; Gastrointestinal Neoplasms; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Neoplasms | 1990 |
77 other study(ies) available for irinotecan and Breast Cancer
| Article | Year |
|---|---|
Syntheses and biological evaluation of topoisomerase I-targeting agents related to 11-[2-(N,N-dimethylamino)ethyl]-2,3-dimethoxy-8,9-methylenedioxy-11H-isoquino[4,3-c]cinnolin-12-one (ARC-31).
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Enzyme Inhibitors; Female; Humans; Magnetic Resonance Spectroscopy; Mass Spectrometry; Mice; Mice, Nude; Neoplasms; Quinolones; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays | 2008 |
Macrocyclic pyridyl polyoxazoles: selective RNA and DNA G-quadruplex ligands as antitumor agents.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Carrier Proteins; Cell Line, Tumor; DNA; Drug Screening Assays, Antitumor; G-Quadruplexes; Humans; Ligands; Macrocyclic Compounds; Mice; Mice, Nude; Neoplasm Proteins; Oxazoles; Pyridines; RNA; Xenograft Model Antitumor Assays | 2010 |
Synergistic Interactions of Cannabidiol with Chemotherapeutic Drugs in MCF7 Cells: Mode of Interaction and Proteomics Analysis of Mechanisms.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cannabidiol; Cell Line, Tumor; Cell Survival; Dactinomycin; Docetaxel; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Irinotecan; MCF-7 Cells; Paclitaxel; Proteome; Proteomics; Vinorelbine | 2021 |
Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Topics: Animals; Apoptosis; B7-H1 Antigen; Breast Neoplasms; Carcinoma, Hepatocellular; CD8-Positive T-Lymphocytes; Cell Proliferation; Female; Forkhead Box Protein O3; Gene Expression Regulation, Neoplastic; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Irinotecan; Killer Cells, Natural; Liver Neoplasms; Mice; Mice, Inbred C57BL; Ovarian Neoplasms; Prognosis; Programmed Cell Death 1 Receptor; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Tumor Microenvironment | 2021 |
Characterization of SN38-resistant T47D breast cancer cell sublines overexpressing BCRP, MRP1, MRP2, MRP3, and MRP4.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; DNA; Drug Resistance, Neoplasm; Female; Fluorescent Dyes; Humans; Irinotecan; Multidrug Resistance-Associated Proteins; Neoplasm Proteins | 2022 |
Alteration of Trop-2 expression in breast cancer cells by clinically used therapeutic agents and acquired tamoxifen resistance.
Topics: Antigens, Neoplasm; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Irinotecan; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; Tamoxifen; Transcription Factors; Triple Negative Breast Neoplasms | 2022 |
Pretherapy Ferumoxytol-enhanced MRI for Metastatic Breast Cancer: A New Approach for Predicting Tumor Delivery of Macromolecular Therapeutics?
Topics: Breast Neoplasms; Contrast Media; Female; Ferrosoferric Oxide; Humans; Irinotecan; Magnetic Resonance Imaging | 2023 |
Label-free drug response evaluation of human derived tumor spheroids using three-dimensional dynamic optical coherence tomography.
Topics: Algorithms; Breast Neoplasms; Colonic Neoplasms; Drug Evaluation; Female; Humans; Irinotecan; Paclitaxel; Tomography, Optical Coherence | 2023 |
Novel carrier-free nanoparticles composed of 7-ethyl-10-hydroxycamptothecin and chlorin e6: Self-assembly mechanism investigation and in vitro/in vivo evaluation.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chlorophyllides; Drug Screening Assays, Antitumor; Irinotecan; Mice; Molecular Dynamics Simulation; Nanoparticles; Particle Size; Photochemotherapy; Photosensitizing Agents; Porphyrins; Surface Properties; Thermodynamics | 2020 |
Synergistic action of doxorubicin and 7-Ethyl-10-hydroxycamptothecin polyphosphorylcholine polymer prodrug.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Doxorubicin; Drug Screening Assays, Antitumor; Humans; Irinotecan; MCF-7 Cells; Mice; Mice, Inbred BALB C; Micelles; Molecular Structure; Particle Size; Phosphorylcholine; Polymers; Prodrugs; Surface Properties | 2020 |
Pilot Study of Irinotecan and S-1 (IRIS) for Advanced and Metastatic Breast Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Drug Combinations; Female; Humans; Irinotecan; Middle Aged; Oxonic Acid; Pilot Projects; Progression-Free Survival; Tegafur | 2020 |
Reducing PD-L1 expression with a self-assembled nanodrug: an alternative to PD-L1 antibody for enhanced chemo-immunotherapy.
Topics: Animals; Apoptosis; B7-H1 Antigen; Breast Neoplasms; Cell Proliferation; Female; Humans; Hypoglycemic Agents; Immunotherapy; Irinotecan; Lung Neoplasms; Metformin; Mice; Mice, Inbred BALB C; Nanoparticles; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
Targeting HR Repair as a Synthetic Lethal Approach to Increase DNA Damage Sensitivity by a RAD52 Inhibitor in BRCA2-Deficient Cancer Cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; BRCA2 Protein; Breast Neoplasms; Cell Proliferation; Curcumin; DNA Damage; DNA Repair; Female; Gene Expression Regulation, Neoplastic; Homologous Recombination; Humans; Irinotecan; Mice; Mice, Nude; Mutation; Rad52 DNA Repair and Recombination Protein; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
Effect of irinotecan on HMGB1, MMP9 expression, cell cycle, and cell growth in breast cancer (MCF-7) cells.
Topics: Acetylation; Apoptosis; Breast Neoplasms; Camptothecin; Cell Cycle; Cell Proliferation; Cell Survival; Female; Gene Expression Regulation, Neoplastic; HMGB1 Protein; Humans; Irinotecan; Matrix Metalloproteinase 9; MCF-7 Cells; Poly(ADP-ribose) Polymerases | 2017 |
Role of AXL in invasion and drug resistance of colon and breast cancer cells and its association with p53 alterations.
Topics: Animals; Axl Receptor Tyrosine Kinase; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Doxorubicin; Fluorouracil; Gene Expression Regulation, Neoplastic; Gene Silencing; HCT116 Cells; HeLa Cells; Humans; Irinotecan; MCF-7 Cells; Mice, Knockout; Mutation; Neoplasm Invasiveness; Oligonucleotide Array Sequence Analysis; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; RNA, Small Interfering; Signal Transduction; Treatment Outcome; Tumor Suppressor Protein p53 | 2017 |
Irinotecan/IR-820 coloaded nanocomposite as a cooperative nanoplatform for combinational therapy of tumor.
Topics: Animals; Breast Neoplasms; Cell Proliferation; Doxorubicin; Drug Delivery Systems; Female; Humans; Indocyanine Green; Irinotecan; MCF-7 Cells; Mice; Nanocomposites; Silicon Dioxide; Xenograft Model Antitumor Assays | 2018 |
Analysis of the activity and safety of weekly low-dose bevacizumab-based regimens in heavily pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Etoposide; Female; Humans; Irinotecan; Methotrexate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pemetrexed; Progression-Free Survival; Treatment Outcome | 2018 |
Cargo-Free Nanomedicine with pH Sensitivity for Codelivery of DOX Conjugated Prodrug with SN38 To Synergistically Eradicate Breast Cancer Stem Cells.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Carriers; Drug Combinations; Drug Compounding; Drug Liberation; Drug Synergism; Female; Humans; Hydrogen-Ion Concentration; Irinotecan; MCF-7 Cells; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplastic Stem Cells; Prodrugs; Theranostic Nanomedicine; Xenograft Model Antitumor Assays | 2018 |
Risk factors for severe adverse effects and treatment-related deaths in Japanese patients treated with irinotecan-based chemotherapy: a postmarketing survey.
Topics: Aged; Analysis of Variance; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Camptothecin; Colorectal Neoplasms; Death; Diarrhea; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Irinotecan; Japan; Leukopenia; Logistic Models; Lung Neoplasms; Lymphoma; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Product Surveillance, Postmarketing; Risk Assessment; Risk Factors; Sex Factors; Skin Neoplasms; Stomach Neoplasms; Thrombocytopenia | 2013 |
Etirinotecan pegol: an option for late-stage breast cancer?
Topics: Breast Neoplasms; Camptothecin; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Irinotecan; Polyethylene Glycols; Topoisomerase I Inhibitors | 2013 |
PEG-coated irinotecan cationic liposomes improve the therapeutic efficacy of breast cancer in animals.
Topics: Animals; Bone Marrow; Breast Neoplasms; Camptothecin; Cations; Cell Line, Tumor; Cell Survival; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Female; Humans; Injections, Intravenous; Irinotecan; Lipids; Liposomes; Mice; Mice, Inbred BALB C; Mice, Nude; Particle Size; Polyethylene Glycols; Rats; Rats, Sprague-Dawley; Surface Properties; Tissue Distribution; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays | 2013 |
Reprogramming ovarian and breast cancer cells into non-cancerous cells by low-dose metformin or SN-38 through FOXO3 activation.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Damage; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Histones; Irinotecan; Metformin; Mice, Nude; Neoplastic Stem Cells; Ovarian Neoplasms; Phosphorylation; Protein Processing, Post-Translational; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Transcriptional targeting of human liver carboxylesterase (hCE1m6) and simultaneous expression of anti-BCRP shRNA enhances sensitivity of breast cancer cells to CPT-11.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Breast Neoplasms; Camptothecin; Carboxylic Ester Hydrolases; Cell Proliferation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Mutation; Neoplasm Proteins; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tumor Cells, Cultured | 2014 |
Irinotecan as a palliative therapy for metastatic breast cancer patients after previous chemotherapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Meta-Analysis as Topic; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Salvage Therapy; Survival Rate | 2014 |
Selective anticancer activity of hirsutine against HER2‑positive breast cancer cells by inducing DNA damage.
Topics: Alkaloids; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Camptothecin; Caspases; Cell Line, Tumor; DNA Damage; Female; Gene Expression Regulation, Neoplastic; Histones; Humans; Irinotecan; MCF-7 Cells; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2 | 2015 |
Iterative and prolonged remission in metastatic breast cancer using pegylated irinotecan: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Female; Humans; Irinotecan; Middle Aged; Neoplasms; Remission Induction; Topoisomerase I Inhibitors | 2015 |
Genome-wide lentiviral shRNA screen identifies serine/arginine-rich splicing factor 2 as a determinant of oncolytic virus activity in breast cancer cells.
Topics: Apoptosis; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Gene Knockout Techniques; Genomics; Herpesvirus 1, Human; Humans; Irinotecan; Lentivirus; Oncolytic Virotherapy; Phosphorylation; RNA, Small Interfering; Serine-Arginine Splicing Factors; Virus Replication | 2016 |
NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Blood-Brain Barrier; Brain; Brain Neoplasms; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Disease Models, Animal; Drug Monitoring; Female; Humans; Irinotecan; Luminescent Measurements; Mice; Molecular Structure; Permeability; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines.
Topics: Antigens, Neoplasm; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Dosage; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; MCF-7 Cells; Neoplasm Proteins; Poly-ADP-Ribose Binding Proteins; Taxoids | 2016 |
Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Long Term Adverse Effects; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2016 |
Combining ABCG2 Inhibitors with IMMU-132, an Anti-Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Camptothecin; Cell Adhesion Molecules; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Flow Cytometry; Gene Expression; Humans; Immunoconjugates; Inhibitory Concentration 50; Irinotecan; Mice; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2016 |
GSK-3 inhibition overcomes chemoresistance in human breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Drug Resistance, Neoplasm; Female; Glycogen Synthase Kinase 3 beta; Humans; Indoles; Irinotecan; Maleimides; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Protein Kinase Inhibitors; Signal Transduction; Time Factors; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
[Evaluation of irinotecan hydrochloride (CPT-11) and trastuzumab combination therapy as salvage treatment in patients with HER2 overexpressing metastatic breast cancer].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Disease Progression; Humans; Immunotherapy; Irinotecan; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Salvage Therapy; Survival Rate; Trastuzumab; Treatment Outcome | 2009 |
Small cell carcinoma of the breast.
Topics: Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carboplatin; Carcinoma, Small Cell; Female; Humans; Irinotecan; Neoplasm Recurrence, Local; Radiotherapy Dosage; Radiotherapy, Adjuvant | 2009 |
Synergistic interactions between aminoflavone, paclitaxel and camptothecin in human breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Colony-Forming Units Assay; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; DNA; Drug Synergism; Enzyme Induction; Female; Flavonoids; Humans; Irinotecan; Paclitaxel | 2010 |
[Utility of CPT-11 as salvage chemotherapy for progressive or recurrent breast cancer patients with multiple drug resistance].
Topics: Adult; Aged; Breast Neoplasms; Camptothecin; Diarrhea; Disease Progression; Drug Resistance, Multiple; Humans; Irinotecan; Middle Aged; Neutropenia; Recurrence; Salvage Therapy | 2010 |
The acridone derivative MBLI-87 sensitizes breast cancer resistance protein-expressing xenografts to irinotecan.
Topics: Acridines; Acridones; Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; HEK293 Cells; Humans; Irinotecan; Mice; Mice, SCID; Neoplasm Proteins; Neoplasm Transplantation; Transplantation, Heterologous | 2011 |
[A case of spindle cell carcinoma of the breast, in which irinotecan was effective against respiratory failure due to pulmonary metastases].
Topics: Antineoplastic Agents, Phytogenic; Biopsy, Needle; Breast Neoplasms; Camptothecin; Carcinoma; Fatal Outcome; Female; Humans; Irinotecan; Lung Neoplasms; Middle Aged; Respiratory Insufficiency; Tomography, X-Ray Computed | 2011 |
Few positives for triple-negative breast cancer.
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Breast Neoplasms; Camptothecin; Chemistry, Pharmaceutical; Disease-Free Survival; Epothilones; Female; Genes, BRCA1; Humans; Irinotecan; Parity; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Risk Factors; Treatment Outcome; Tubulin Modulators | 2011 |
MC70 potentiates doxorubicin efficacy in colon and breast cancer in vitro treatment.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biphenyl Compounds; Breast Neoplasms; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colonic Neoplasms; Doxorubicin; Drug Synergism; Female; Genomics; Humans; Irinotecan; Kinetics; Multidrug Resistance-Associated Proteins; Necrosis; Neoplasm Proteins; Signal Transduction; Tetrahydroisoquinolines; Topotecan | 2011 |
The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation.
Topics: Androstadienes; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Proliferation; Chromones; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Irinotecan; Morpholines; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Transport; Proto-Oncogene Proteins c-akt; Topotecan; Wortmannin | 2012 |
Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Camptothecin; Cell Cycle; Cell Line, Tumor; Checkpoint Kinase 1; DNA Damage; DNA, Neoplasm; Female; Genes, cdc; Genes, erbB-2; Genes, p53; Humans; Irinotecan; Mice; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Neoplasm Proteins; Protein Kinase Inhibitors; Protein Kinases; Receptors, Estrogen; Receptors, Progesterone; Staurosporine; Thiophenes; Tumor Suppressor Protein p53; Urea; Xenograft Model Antitumor Assays | 2012 |
Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Camptothecin; Cell Cycle; Cell Line, Tumor; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Irinotecan; Neoplastic Stem Cells; Phosphorylation; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Receptor, ErbB-2 | 2014 |
BBA, a derivative of 23-hydroxybetulinic acid, potently reverses ABCB1-mediated drug resistance in vitro and in vivo.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Breast Neoplasms; Calcium Channel Blockers; Camptothecin; Carcinoma, Hepatocellular; Cell Proliferation; Cells, Cultured; Cisplatin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Fluorescent Antibody Technique; Humans; In Vitro Techniques; Irinotecan; KB Cells; Liver Neoplasms; Male; Mice; Mice, Nude; Models, Molecular; Molecular Docking Simulation; Paclitaxel; Piperidines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Triterpenes; Verapamil | 2012 |
Novel SN38 conjugate-forming nanoparticles as anticancer prodrug: in vitro and in vivo studies.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Survival; Chromatography, High Pressure Liquid; Drug Stability; Female; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Mice, Nude; Micelles; Nanoparticles; Prodrugs; Solubility; Tetrazolium Salts; Thiazoles; Xenograft Model Antitumor Assays | 2013 |
[Importance and practice of UGT1A1 polymorphisms].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Female; Glucuronosyltransferase; Humans; Irinotecan; Polymorphism, Genetic | 2012 |
Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Camptothecin; Colon; Diarrhea; Intestine, Small; Irinotecan; Male; Neoplasm Transplantation; Rats; Severity of Illness Index | 2003 |
Ex vivo analysis of topotecan: advancing the application of laboratory-based clinical therapeutics.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; In Vitro Techniques; Irinotecan; Lethal Dose 50; Lung Neoplasms; Male; Neoplasms; Prostatic Neoplasms; Topotecan; Tumor Cells, Cultured | 2003 |
[Retrospective study on utility of irinotecan hydrochloride in patients with advanced and recurrent breast cancer].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Bridged-Ring Compounds; Camptothecin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Middle Aged; Retrospective Studies; Survival Rate; Taxoids | 2003 |
Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
Topics: Aminocoumarins; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Coumarins; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Irinotecan; Lung Neoplasms; Mitoxantrone; Neoplasm Proteins; Novobiocin; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 2004 |
Pheophorbide a is a specific probe for ABCG2 function and inhibition.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Chlorophyll; Drug Resistance, Neoplasm; Humans; Irinotecan; Neoplasm Proteins; Quinolines; Staurosporine; Topotecan | 2004 |
[Molecular biology methods in cancer medicine: options beyond steel instrument, ray and chemotherapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bevacizumab; Breast Neoplasms; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Female; Humans; Immunotherapy; Irinotecan; Male; Mutation; Neoplasms; Prostatic Neoplasms; Research; Simplexvirus; Trastuzumab; Vascular Endothelial Growth Factor A | 2004 |
Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Topics: Adenosine Triphosphate; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport, Active; Breast Neoplasms; Camptothecin; Carcinoma, Small Cell; Cell Line, Tumor; Cell Membrane; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Mitoxantrone; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Topotecan | 2005 |
[A case of recurrent breast cancer with bone metastasis causing pancytopenia--efficacy of low-dose CPT-11+ MPA].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Mastectomy, Segmental; Medroxyprogesterone Acetate; Middle Aged; Pancytopenia; Quality of Life | 2005 |
Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independen
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Camptothecin; Caspase 3; Caspase Inhibitors; Caspases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Cysteine Proteinase Inhibitors; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Fluorouracil; Folic Acid Antagonists; Glutamates; Guanine; HT29 Cells; Humans; Intracellular Signaling Peptides and Proteins; Irinotecan; Oligopeptides; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Protein Serine-Threonine Kinases; Quinazolines; rho-Associated Kinases; Thymidylate Synthase; Time Factors; Topoisomerase I Inhibitors | 2005 |
Expression of drug pathway proteins is independent of tumour type.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; Camptothecin; Colonic Neoplasms; Cytochrome P-450 Enzyme System; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Immunohistochemistry; Irinotecan; Lung Neoplasms; Lymphoma; Male; Melanoma; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Tissue Array Analysis | 2006 |
Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy.
Topics: Animals; Breast Neoplasms; Camptothecin; Colonic Neoplasms; Drug Delivery Systems; Drug Stability; Female; HT29 Cells; Humans; Irinotecan; Liposomes; Mice; Mice, Nude; Nanostructures; Rats; Rats, Sprague-Dawley; Xenograft Model Antitumor Assays | 2006 |
[A case of pericardial tamponade caused by recurrent breast cancer treated with intrapericardial and intrapleural infusion of cisplatin (CDDP)].
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Carcinoma, Ductal, Breast; Cardiac Tamponade; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Infusions, Intralesional; Irinotecan; Pericardial Effusion; Pericardiocentesis; Pleural Effusion, Malignant; Pleural Neoplasms | 2006 |
Cellular FLICE-inhibitory protein regulates chemotherapy-induced apoptosis in breast cancer cells.
Topics: Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Camptothecin; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 8; Cell Line, Tumor; Dose-Response Relationship, Drug; Down-Regulation; Etoposide; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Interferon-gamma; Irinotecan; Mitoxantrone | 2007 |
Sensitivity to CPT-11 and platinum derivatives of stage I/II node-negative breast, lung, and gastric cancer with occult neoplastic cells in lymph node sinuses.
Topics: Antineoplastic Agents, Phytogenic; bcl-2-Associated X Protein; Breast Neoplasms; Camptothecin; DNA Topoisomerases, Type I; DNA-Binding Proteins; Endonucleases; Humans; Immunoenzyme Techniques; Irinotecan; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Polymerase Chain Reaction; Stomach Neoplasms; Topoisomerase I Inhibitors | 2007 |
Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Carcinoma; Cell Proliferation; Colorectal Neoplasms; Disease Models, Animal; Drug Delivery Systems; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Mice; Mice, Nude; Models, Biological; Neoplasms; Pancreatic Neoplasms; Polyethylene Glycols; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
Primary small cell carcinoma of the breast.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carboplatin; Carcinoma, Small Cell; Etoposide; Fatal Outcome; Female; Humans; Irinotecan; Liver Neoplasms; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Thoracic Wall | 2009 |
[Four cases of recurrent breast cancer effectively treated by the new antitumor agent, CPT-11 (irinotecan)].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Camptothecin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Lymphatic Metastasis; Mastectomy, Radical; Middle Aged; Soft Tissue Neoplasms | 1994 |
Interleukin-1 alpha-induced modulation of topoisomerase I activity and DNA damage: implications in the mechanisms of synergy with camptothecins in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Biological Transport; Blotting, Western; Breast Neoplasms; Camptothecin; Cell Nucleus; Cell Survival; DNA Damage; DNA Topoisomerases, Type I; Drug Administration Schedule; Drug Synergism; Electrophoresis, Polyacrylamide Gel; Female; Humans; Interleukin-1; Irinotecan; Mice; Mice, Nude; Nuclear Proteins; Ovarian Neoplasms; Protein Biosynthesis; Recombinant Proteins; Transcription, Genetic; Transplantation, Heterologous | 1996 |
Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Line; Cell Survival; Colonic Neoplasms; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Female; Gene Amplification; Gene Expression; Genetic Variation; Humans; In Situ Hybridization, Fluorescence; Irinotecan; Karyotyping; Kinetics; Nuclear Proteins; Tumor Cells, Cultured | 1996 |
Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Colonic Neoplasms; Humans; Irinotecan; Kidney Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Stomach Neoplasms; Subrenal Capsule Assay; Tumor Cells, Cultured | 1998 |
Water soluble 20(S)-glycinate esters of 10,11-methylenedioxycamptothecins are highly active against human breast cancer xenografts.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cholinesterase Inhibitors; Drug Screening Assays, Antitumor; Esters; Female; Glycine; Humans; Infant, Newborn; Irinotecan; Mice; Mice, Nude; Molecular Structure; Neoplasm Transplantation; Solubility; Structure-Activity Relationship; Tumor Cells, Cultured | 1999 |
Fish oil supplementation enhanced CPT-11 (irinotecan) efficacy against MCF7 breast carcinoma xenografts and ameliorated intestinal side-effects.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Camptothecin; Colon; Corn Oil; Drug Synergism; Duodenum; Female; Fish Oils; Gastrointestinal Diseases; Humans; Irinotecan; Lipid Peroxidation; Mice; Mice, Nude; Muscle, Smooth; Thiobarbituric Acid Reactive Substances; Transplantation, Heterologous; Tumor Cells, Cultured | 1999 |
Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Cell Survival; DNA Damage; Drug Resistance, Multiple; Epirubicin; Female; Glucuronides; Glucuronosyltransferase; Humans; Irinotecan; Microscopy, Confocal; Mitoxantrone; Polymerase Chain Reaction; Topotecan; Tumor Cells, Cultured | 1999 |
Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothe cin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-kappaB activation.
Topics: Adenoviridae; Animals; Apoptosis; Breast Neoplasms; Camptothecin; Cell Nucleus; Colorectal Neoplasms; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Inhibitors; Female; Humans; I-kappa B Proteins; Immunohistochemistry; In Situ Nick-End Labeling; Irinotecan; Mice; Mice, Nude; NF-kappa B; NF-KappaB Inhibitor alpha; Time Factors; Transgenes; Tumor Cells, Cultured | 2000 |
Highlights of the Eighth European Cancer Conference.
Topics: Amifostine; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Docetaxel; Head and Neck Neoplasms; Humans; Irinotecan; Neoplasms; Paclitaxel; Radiation Injuries; Radiation-Protective Agents; Taxoids; Vinblastine; Vinorelbine | 1995 |
Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Genes, MDR; Genetic Vectors; HeLa Cells; Humans; Irinotecan; Mitoxantrone; Mutation; Neoplasm Proteins; Rhodamine 123; RNA, Messenger; Substrate Specificity; Topotecan; Transfection; Tumor Cells, Cultured; Vaccinia virus | 2001 |
Clinical effect of irinotecan in advanced and metastatic breast cancer patients previously treated with doxorubicin- and docetaxel-containing regimens.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Middle Aged; Paclitaxel; Retrospective Studies; Salvage Therapy; Survival Analysis; Taxoids | 2001 |
[Globalization of anti-cancer therapies].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carboplatin; Cisplatin; Colorectal Neoplasms; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasms; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Stomach Neoplasms | 2002 |
DNA damage is able to induce senescence in tumor cells in vitro and in vivo.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; beta-Galactosidase; Breast Neoplasms; Camptothecin; Cell Cycle; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; DNA Damage; Etoposide; Humans; Irinotecan; Neoadjuvant Therapy; Tumor Suppressor Protein p53 | 2002 |
Estrone and 17beta-estradiol reverse breast cancer resistance protein-mediated multidrug resistance.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Estrone; Female; Flow Cytometry; Humans; Irinotecan; K562 Cells; Mitoxantrone; Neoplasm Proteins; Topoisomerase I Inhibitors; Topotecan; Transfection | 2002 |
Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, phar
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Breast Neoplasms; Camptothecin; Colonic Neoplasms; Cyclic AMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Oligonucleotides; Oligonucleotides, Antisense; Prostatic Neoplasms; Survival Rate; Tissue Distribution; Treatment Outcome | 2002 |